First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study - Summary - MDSpire

First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study

  • By

  • Wan Zhang

  • Xiaojun Yang

  • Hualin Chen

  • Xingxiang Pu

  • Reyihanguli Tuohetashi

  • Xuan Wu

  • Zhanhong Xie

  • Di Wu

  • Yongguang Cai

  • Shi Jin

  • Xuli Guo

  • Kaitao Yao

  • Yongfeng Chen

  • Guanming Jiang

  • June 8, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of first-line serplulimab combined with chemotherapy versus chemotherapy alone in SCLC patients with brain metastases.

Key Findings:
  • 62 patients with SCLC and confirmed brain metastases were included.
  • Serplulimab combined with chemotherapy achieved an intracranial objective response rate of 78.57%.
  • Median iPFS was significantly prolonged in the serplulimab group (8.93 months vs. 6.37 months; log-rank P = 0.004).
  • Median OS was also significantly prolonged (28.77 months vs. 12.95 months; log-rank P < 0.001).
  • Addition of cranial radiotherapy to immunotherapy significantly augmented survival benefits.
  • Safety profiles were manageable with no new safety signals identified.
Interpretation:

Remove unsupported conclusions and focus on summarizing findings.

Limitations:
  • The study's findings may not be generalizable due to the specific patient population and multicenter design.
  • The sample size of 62 patients may limit the statistical power of the results.
Conclusion:

Revise to eliminate unsupported claims and focus on study results.

Original Source(s)

First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study

  • by Wan Zhang, Xiaojun Yang, Hualin Chen, Xingxiang Pu, Reyihanguli Tuohetashi, Xuan Wu, Zhanhong Xie, Di Wu, Yongguang Cai, Shi Jin, Xuli Guo, Kaitao Yao, Yongfeng Chen, Guanming Jiang

  • June 8, 2026

Related Content

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer

Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study